282 related articles for article (PubMed ID: 28376920)
1. Molecular clonality analysis of esophageal adenocarcinoma by multiregion sequencing of tumor samples.
van Nistelrooij AM; van Marion R; Koppert LB; Biermann K; Spaander MC; Tilanus HW; van Lanschot JJ; Wijnhoven BP; Dinjens WN
BMC Res Notes; 2017 Apr; 10(1):144. PubMed ID: 28376920
[TBL] [Abstract][Full Text] [Related]
2. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations.
Hardie LJ; Darnton SJ; Wallis YL; Chauhan A; Hainaut P; Wild CP; Casson AG
Cancer Lett; 2005 Jan; 217(2):221-30. PubMed ID: 15617840
[TBL] [Abstract][Full Text] [Related]
3. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
4. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
[TBL] [Abstract][Full Text] [Related]
5. Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma.
Zhuang Z; Vortmeyer AO; Mark EJ; Odze R; Emmert-Buck MR; Merino MJ; Moon H; Liotta LA; Duray PH
Cancer Res; 1996 May; 56(9):1961-4. PubMed ID: 8616831
[TBL] [Abstract][Full Text] [Related]
6. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus.
Dolan K; Garde J; Walker SJ; Sutton R; Gosney J; Field JK
Hum Pathol; 1999 Dec; 30(12):1508-14. PubMed ID: 10667431
[TBL] [Abstract][Full Text] [Related]
7. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.
González MV; Artímez ML; Rodrigo L; López-Larrea C; Menéndez MJ; Alvarez V; Pérez R; Fresno MF; Pérez MJ; Sampedro A; Coto E
J Clin Pathol; 1997 Mar; 50(3):212-7. PubMed ID: 9155671
[TBL] [Abstract][Full Text] [Related]
8. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
9. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.
Wong DJ; Paulson TG; Prevo LJ; Galipeau PC; Longton G; Blount PL; Reid BJ
Cancer Res; 2001 Nov; 61(22):8284-9. PubMed ID: 11719461
[TBL] [Abstract][Full Text] [Related]
10. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
Galipeau PC; Li X; Blount PL; Maley CC; Sanchez CA; Odze RD; Ayub K; Rabinovitch PS; Vaughan TL; Reid BJ
PLoS Med; 2007 Feb; 4(2):e67. PubMed ID: 17326708
[TBL] [Abstract][Full Text] [Related]
11. Targeted next-generation sequencing of commonly mutated genes in esophageal adenocarcinoma patients with long-term survival.
Visser E; Franken IA; Brosens LAA; de Leng WWJ; Strengman E; Offerhaus JA; Ruurda JP; van Hillegersberg R
Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859360
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
[TBL] [Abstract][Full Text] [Related]
13. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma.
Maley CC; Galipeau PC; Li X; Sanchez CA; Paulson TG; Blount PL; Reid BJ
Cancer Res; 2004 Oct; 64(20):7629-33. PubMed ID: 15492292
[TBL] [Abstract][Full Text] [Related]
14. INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma.
Vieth M; Schneider-Stock R; Röhrich K; May A; Ell C; Markwarth A; Roessner A; Stolte M; Tannapfel A
Virchows Arch; 2004 Aug; 445(2):135-41. PubMed ID: 15185075
[TBL] [Abstract][Full Text] [Related]
15. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Fontolliet C; Bosman FT; Benhattar J
Gastroenterology; 2002 Apr; 122(4):1113-21. PubMed ID: 11910361
[TBL] [Abstract][Full Text] [Related]
16. Multistage carcinogenesis in Barrett's esophagus.
Maley CC
Cancer Lett; 2007 Jan; 245(1-2):22-32. PubMed ID: 16713672
[TBL] [Abstract][Full Text] [Related]
17. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
[TBL] [Abstract][Full Text] [Related]
18. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus].
Schneider PM; Hölscher AH; Wegerer S; König U; Becker K; Siewert JR
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):495-9. PubMed ID: 14518305
[TBL] [Abstract][Full Text] [Related]
20. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett's esophagus.
Rudolph RE; Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
J Natl Cancer Inst; 2003 May; 95(10):750-7. PubMed ID: 12759393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
